Evidence map›Paper›PMID 27921232›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2017

Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2.

Q Li, S Lu, X Li, G Hou, L Yan, W Zhang, B Qiao

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Q LiDepartment of Urology, The First Affiliated Hospital, Zhengzhou University, Institute of Urology of Henan Province, No 1, Jianshe East Road, Zhengzhou, 450052, Henan, China. li_rechee@163.com.
S LuDepartment of Urology, The First Affiliated Hospital, Zhengzhou University, Institute of Urology of Henan Province, No 1, Jianshe East Road, Zhengzhou, 450052, Henan, China.
X LiDepartment of Neonatel Intensive Care Unit, Zhengzhou First People's Hospital, Zhengzhou, 450004, China.
G HouCollege of Pharmacy, Zhengzhou University, Zhengzhou, 450001, China.
L YanDepartment of Urology, The First Affiliated Hospital, Zhengzhou University, Institute of Urology of Henan Province, No 1, Jianshe East Road, Zhengzhou, 450052, Henan, China.
W ZhangDepartment of Urology, The First Affiliated Hospital, Zhengzhou University, Institute of Urology of Henan Province, No 1, Jianshe East Road, Zhengzhou, 450052, Henan, China.
B QiaoDepartment of Urology, The First Affiliated Hospital, Zhengzhou University, Institute of Urology of Henan Province, No 1, Jianshe East Road, Zhengzhou, 450052, Henan, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou People's Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRecent studies have identified Engrailed-2 (EN-2), a homeobox-containing transcription factor, as a candidate oncogene in prostate cancer (PC). Therapeutic targeting on EN-2, however, is limited because the mechanism underlying EN-2 overexpression in prostatic cancer cells is unknown. This study was to investigate the potential regulatory role of miR-33a on EN-2 expression and explore this signaling axis in ability of prostate cancer survival and metastasis.

methodsThe relative expression of miR-33a and EN-2 in paired prostate cancer tissue and adjacent normal tissue as well as in prostate cancer cell lines, PC3 and DU145, was determined using quantitative real-time PCR or western blot, respectively. Cells survival, migration and invasion were evaluated by assays of MTT, TUNEL and Boyden chamber assays, respectively. Direct regulation of EN-2 by miR-33a was examined by luciferase reporter assay.

resultsThe data showed that miR-33a was upregulated and EN-2 was downregulated in both prostate cancer tissue and prostate cancer cells. miR-33a overexpression suppresses prostate cancer cell survival and metastasis. miR-33a can directly act on EN-2 expression by binding to 3'UTR of its mRNA. Also, miR-33a negatively regulated EN-2 mRNA and protein expression. In pcDNA-EN-2 and miR-33a mimic co-transfected PC3 and DU145 cells, EN-2 overexpression reverses the anti-cell survival and metastasis actions of miR-33a overexpression. The pivotal role of miR-33a in inhibiting prostate tumor growth was confirmed in xenograft models of prostate cancer.

conclusionOur data suggest that the functional interaction of miR-33a and EN-2 is involved in tumorigenesis of prostate cancer. Also in this process EN-2 serves as a negative responder for miR-33a.

Indexed as

AnimalsApoptosisBlotting, WesternCell Line, TumorCell MovementCell ProliferationDown-RegulationEngrailed 2 ProteinGene Expression Regulation, NeoplasticHeterograftsHomeodomain ProteinsHumansIn Situ Nick-End LabelingMaleMiceMice, Inbred C57BLEngrailed 2 ProteinHomeodomain ProteinsMicroRNAsMIRN33a microRNA, humanNerve Tissue ProteinsEngrailed-2MigrationMiR-33aProstate cancer

Identifiers

PMID27921232
OpenAlexW2559991268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.